Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Rashmi Kumari

SHOCKING: Gilead sciences stock analyst estimates ratings - What They Never Told You

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and delivering innovative therapies to treat life-threatening diseases, with a focus on areas such as virology, oncology, and inflammatory diseases. 

Shares of GILD have underperformed the broader market over the past year. The stock has gained 21.5% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 36.4%. In 2024, GILD is up 20.9% compared to SPX’s 25.2% rise on a YTD basis.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.